Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSH2-/- Tumor Cell Vaccines in Advanced pMMR Colorectal Cancer
NCT07510308Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2026
- Primary completion
- Nov 2026
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of MSH2-/- tumor cell vaccine in colorectal cancer (CRC) (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Dose-Limiting Toxicities and Treatment-Emergent Adverse Events at 12 months. Started Jun 2026; status: recruiting.
02
Drugs
MSH2-/- tumor cell vaccine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07510308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07510308.